DRG Market Assessment reports

In 2021, sales of branded biologics in ophthalmology totaled more than $9 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2021-2031 forecast period, the…

In 2021, sales of branded biologics in immunology exceeded $70 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this…

In 2021, sales of branded biologics for respiratory indications totaled about $0.7 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2021-2031…

In 2021, sales of branded MAb biologics in oncology exceeded $36 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5…

In 2021, sales of erythropoiesis-stimulating agent (ESA) brands and biosimilars at the ex-manufacturer price level totaled more than $2.5 billion in the major pharmaceutical markets under study (…

Payers play a significant role in determining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential…

The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…

The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 680 currently available and novel biosimilar products, detailing…

Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity to…

In the last decade, the biosimilar therapy market has been growing, led mainly by two therapeutic areas: immunology and oncology. It now continues to expand into new fields. To enhance this growth…

In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…

Biosimilars of erythropoiesis-stimulating agents (ESAs) entered the European market a decade ago, but the FDA did not approve the first ESA biosimilar—Retacrit—until June 2018; it launched in…